Best-in-class intracellular delivery platform

Enabling next gen therapeutics through endosomal escape

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement.
The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity.
This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Science

The Challenge: Endolysosomal trapping of macromolecules

One of the greatest challenges for efficacy of macromolecule therapeutics that act on an intracellular level, is delivery into key cells. Macromolecule therapeutics nowadays rely on receptor-mediated endocytosis into the endosomal compartment. The endo-lysosomal membranes, however, prohibit efficient cytoplasmic access of such foreign substances. The therapeutic efficacy of such drugs is therefore highly dependent on endo-lysosomal vesicles degradation.
Cytosolic delivery of macromolecule therapeutics requires incredibly challenging technical optimizations or specialized drug delivery platforms. For most oligonucleotide-based therapeutics, delivery remains an unsolved problem and exposes a significant need for the development of novel delivery mechanisms.

Our Approach: ENDOSCAPE®

At Sapreme, we are developing improved macromolecule delivery mechanisms by circumventing endosomal entrapment. Our ENDOSCAPE® platform is based on compounds which can release trapped cargo from the endo-lysosomal membranes, improving the therapeutic window and enabling access to intracellular targets with minimal toxicity.
By binding our technology to antibody-conjugated toxins and oligonucleotides, our goal is to enhance target engagement and improve therapeutic efficacy without limitation to biologic modality or indication.

News & Events

Upcoming Events

No upcoming event attendances scheduled.

Press Releases

Bilthoven, July 20, 2023

Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors

Sapreme announced today the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors. Both bring a wealth of executive, business and clinical development expertise from large pharmaceutical and innovative biotech companies as Sapreme now builds upon preclinical proof of concept in several disease indications and delivery models. Read the full press release here.

 

October 7, 2021

Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities. Led by founding investor Aglaia Oncology Funds, together with Aglaia-associated partners, the round follows promising 2020 and 2021 preclinical data demonstrating the effectiveness of Sapreme’s endosomal escape compound, SPT001. Read the full release here.

About Sapreme:

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Contacts: Guy Hermans, CEO   |  +31 30 760 09 76   |  hermans@sapreme-technologies.com

For Media Inquiries, please contact: Trophic Communications Eva Mulder or Valeria Fisher  |  +49 89 238 877 30  |  sapreme@trophic.eu

Careers

Sapreme Technologies is a privately-owned biotech company developing a disruptive technology platform (ENDOSCAPE®) enabling the development of superior targeted therapeutics, such as antibody-drug conjugates and oligonucleotide-based drugs. Our latest vacancies have recently been filled successfully. There are no openings at this time. New opportunities will be announced here, and on Sapreme’s linkedin page.

Open applications welcome

If you are a talented individual interested in contributing to our mission, please send your resume to careers@sapreme-technologies.com

Contact

Telephone

+31 30 760 09 76

Address

Antonie van Leeuwenhoeklaan 9
USP Bilthoven A12-1
3721 MA Bilthoven
The Netherlands